Axsome Therapeutics(GB:0HKF)
$148.81+7.38 (+5.22%)
GB:0HKF
Axsome Therapeutics ownership
$148.81
At close:+7.38 (+5.22%)
Axsome Therapeutics (0HKF) Ownership - Who Owns Axsome Therapeutics?
4 Followers
Axsome Therapeutics (0HKF) Ownership Overview
- 15.02% Insiders
- 23.65% Mutual Funds
- 2.88% Other Institutional Investors
- 13.55% ETFs
- 44.90% Public Companies and Individual Investors
The ownership structure of Axsome Therapeutics (GB:0HKF) stock is a mix of institutional, retail, and individual investors. Approximately 40.08% of the company’s stock is owned by Institutional Investors, 15.02% is owned by Insiders, and 44.90% is owned by Public Companies and Individual Investors.
The ownership structure of Axsome Therapeutics (GB:0HKF) stock is a mix of institutional, retail, and individual investors. Approximately 40.08% of the company’s stock is owned by Institutional Investors, 15.02% is owned by Insiders, and 44.90% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|---|---|---|
| Dec 31, 2025 | Graham Capital Management, L.p. | $279,804 | |
| Dec 31, 2025 | Blackstone Inc. | $4,474,680 | |
| Dec 31, 2025 | Bridgewater Associates, Lp | $8,665,172 | |
| Dec 31, 2025 | Royce & Associates Llc | $17,171,264 |
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Tabuteau Herriot | 7,351,729 | Insider | 13.98% | 1,094,010,792 |
| Vanguard | 3,752,570 | Institution | 7.13% | 558,419,942 |
| Vanguard Index Funds | 3,466,204 | Institution | 6.59% | 515,805,817 |
| BlackRock, Inc. | 3,103,708 | Institution | 5.90% | 461,862,787 |
| Ishares | 1,614,611 | Institution | 3.07% | 240,270,263 |
| Delaware Group Equity Funds V | 1,452,975 | Institution | 2.76% | 216,217,210 |
| First Trust | 688,728 | Institution | 1.31% | 102,489,614 |
| Vanguard Explorer Fund | 531,004 | Institution | 1.01% | 79,018,705 |
| Fidelity Select Portfolios | 497,180 | Institution | 0.95% | 73,985,356 |
| Mark Coleman | 434,245 | Insider | 0.83% | 64,619,998 |
Top Mutual Fund Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Vanguard Index Funds | 3,466,204 | Institution | 6.59% | 515,805,817 |
| Delaware Group Equity Funds V | 1,452,975 | Institution | 2.76% | 216,217,210 |
| Vanguard Explorer Fund | 531,004 | Institution | 1.01% | 79,018,705 |
| Fidelity Select Portfolios | 497,180 | Institution | 0.95% | 73,985,356 |
| Fidelity Concord Street Trust | 431,698 | Institution | 0.82% | 64,240,979 |
| Ivy Funds | 418,038 | Institution | 0.79% | 62,208,235 |
| Fidelity Salem Street Trust | 396,340 | Institution | 0.75% | 58,979,355 |
| Mutual Fund Series Trust | 330,193 | Institution | 0.63% | 49,136,020 |
| Franklin Custodian Funds | 300,000 | Institution | 0.57% | 44,643,000 |
| Fidelity Securities Fund | 262,160 | Institution | 0.50% | 39,012,030 |
FAQ
Who Owns Axsome Therapeutics (GB:0HKF)?
According to the latest TipRanks data, approximately 40.08% of the company's stock is held by institutional investors, 15.02% is held by insiders, and 44.90% is held by public companies and individual investors.
What percentage of Axsome Therapeutics (GB:0HKF) stock is held by institutional investors?
According to the latest TipRanks data, approximately 40.08% of Axsome Therapeutics (GB:0HKF) stock is held by institutional investors: 23.65% by mutual funds, 13.55% by ETFs and 2.88% by other institutional investors.
What percentage of Axsome Therapeutics (GB:0HKF) stock is held by retail investors?
According to the latest TipRanks data, approximately 44.90% of Axsome Therapeutics (GB:0HKF) stock is held by public companies and individual investors.
Who owns the most shares of Axsome Therapeutics (GB:0HKF)?
TABUTEAU HERRIOT owns the most shares of Axsome Therapeutics (GB:0HKF).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
